Efficacy News and Research

RSS

Emotion regulation therapy benefits bipolar patients

Dialectical behavior therapy shows promise for the treatment of bipolar disorder, findings from a pilot study show.

6 Feb 2013

Experimental TB vaccine does not protect infants, study shows

"Hopes that a much needed new tuberculosis [TB] vaccine was on the way, the first for 90 years, have been dashed by trial results showing it did not protect babies against the disease," the Guardian reports.

6 Feb 2013

Elan agrees to restructure Tysabri collaboration with Biogen Idec

Elan Corporation, plc today announced that it has agreed to restructure the Tysabri® collaboration with Biogen Idec.

6 Feb 2013

BSD Medical announces results from BSD-2000 hyperthermia system study on pancreatic cancer

BSD Medical Corporation, a leading provider of medical systems that utilize heat therapy to treat cancer, announced the publication of results from a clinical study on advanced pancreatic cancer using the BSD-2000 Hyperthermia System (BSD-2000).

6 Feb 2013

Ramipril may improve pain-free walking among patients with PAD and intermittent claudication

Among patients with peripheral artery disease and intermittent claudication (pain in the calf that comes and goes, typically felt while walking), 24 weeks of treatment with the angiotensin-converting enzyme (ACE) inhibitor ramipril was associated with improvement in pain-free and maximum walking times and the physical health aspect of quality of life, according to a study appearing in the February 6 issue of JAMA.

6 Feb 2013

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Verastem, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced the initiation of a Phase 1/1b trial of VS-6063 in combination with paclitaxel for the treatment of advanced ovarian cancer.

5 Feb 2013

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Acceleron Pharma, a biopharmaceutical company developing protein therapeutics for cancer and orphan disease, today announced that the Gynecologic Oncology Group (GOG) initiated a phase 2 study of dalantercept in patients with persistent or recurrent ovarian, fallopian tube, or primary peritoneal cancer.

5 Feb 2013

Viral conjunctivitis: potential new treatment

Viral conjunctivitis is a highly contagious infection, often causing major ophthalmic epidemics. There is no approved acute treatment currently approved by the FDA for viral conjunctivitis. A safe broad-spectrum antiviral agent is needed to treat this unmet medical need.

5 Feb 2013

Detection of B cells may predict graft-versus-host disease

The ability to detect B cells specific to the DEAD box protein may help predict the development of chronic graft-versus-host disease in male recipients of female hematopoietic cells, according to recent findings.

5 Feb 2013

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

Preliminary evidence from a clinical trial suggests that treatment with glucagon-like peptide-1 (GLP-1) receptor agonists was associated with reduced body mass index and body weight in adolescents with severe obesity, according to a report published Online First by JAMA Pediatrics, a JAMA Network publication.

5 Feb 2013

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX in the U.S. and XIAPEX in Europe and Eurasia, today announced that The Journal of Urology has electronically published the uncorrected proof of the pivotal IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials on its website.

5 Feb 2013

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the first patient began treatment in the Company's Phase IIa dose-escalating clinical trial for ALS.

5 Feb 2013

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

5 Feb 2013

Indian medicines ‘promising’ for osteoarthritis care

Ayurvedic medicine may offer osteoarthritis relief, say Indian researchers who found traditional formulations to be equal to conventional drugs for the improvement of pain and knee function.

4 Feb 2013

SIR, Society for Vascular Surgery partner on IVC filter study

The Society of Interventional Radiology and Society for Vascular Surgery jointly will launch PRESERVE-the first large-scale, multispecialty prospective study to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment.

2 Feb 2013

Low testosterone levels occur more often among men on long-acting opioids

Low testosterone levels occur five times more often among men who take long-acting instead of short-acting opioids for chronic pain, according to a new Kaiser Permanente study published in The Clinical Journal of Pain.

2 Feb 2013

University of Kentucky professor to continue research into ruthenium-based cancer drugs

University of Kentucky assistant professor of chemistry Edith "Phoebe" Glazer has received an American Cancer Society Research Scholar Grant for $715,000 over four years to continue her research into ruthenium-based cancer drugs. These compounds are less toxic to healthy cells than a similar and widely used inorganic drug.

1 Feb 2013

Book reviews psilocybin's potential in alleviating psychological distress in cancer patients

Improvements in the diagnosis and treatment of cancers in recent years have led to a marked increase in patients' physical survival rates. While doctors can treat the physical disease, what is not well understood is how best to address the psychological needs of patients with cancer.

1 Feb 2013

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Merck, known as MSD outside the United States and Canada, today announced financial results for the fourth quarter and full year of 2012.

1 Feb 2013

Microbiologists discover new pathway to improve vaccines against tuberculosis

A new pathway for improving vaccines against tuberculosis has been discovered by microbiologists at the University at Buffalo in collaboration with researchers at other universities, according to a paper in the journal Mucosal Immunology, published by the Nature group.

1 Feb 2013

Efficacy News and Research

Emotion regulation therapy benefits bipolar patients

Experimental TB vaccine does not protect infants, study shows

Elan agrees to restructure Tysabri collaboration with Biogen Idec

BSD Medical announces results from BSD-2000 hyperthermia system study on pancreatic cancer

Ramipril may improve pain-free walking among patients with PAD and intermittent claudication

Verastem commences VS-6063 plus paclitaxel Phase 1/1b trial in advanced ovarian cancer

Acceleron Pharma initiates dalantercept phase 2 study in advanced ovarian cancer

Viral conjunctivitis: potential new treatment

Detection of B cells may predict graft-versus-host disease

GLP-1 receptor agonists associated with reduced BMI in adolescents with severe obesity

The Journal of Urology publishes results from BioSpecifics XIAFLEX trials on Peyronie's disease

BrainStorm initiates NurOwn Phase IIa dose-escalating trial in ALS

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Indian medicines ‘promising’ for osteoarthritis care

SIR, Society for Vascular Surgery partner on IVC filter study

Low testosterone levels occur more often among men on long-acting opioids

University of Kentucky professor to continue research into ruthenium-based cancer drugs

Book reviews psilocybin's potential in alleviating psychological distress in cancer patients

Merck full-year 2012 worldwide sales decrease 2% to $47.3 billion

Microbiologists discover new pathway to improve vaccines against tuberculosis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News